Head-and-neck cancers not only carry poor prognoses, but also reduced quality of life for the patients. Disease control is often achieved at the expense of substantial functional loss and disfigurement. Photodynamic therapy (PDT) is particularly well suited to the treatment of head-and-neck-tumors because it has little effect on underlying functional structures and has an excellent cosmetic outcome. Studies in the past decades have shown that PDT is of similar efficacy as traditional measures in the treatment of early-stage head-and-neck cancers with an overall response rate of 85%-100%, with up to 75% of the complete responses sustained at 2 years after PDT. For advanced head-and-neck cancers, studies were also conducted to evaluate the palliative effects of PDT. Overall, a 58%-70% palliative benefit can be observed in these patients. Using interstitial PDT, the median survival of the patients with recurrent unresectable head-and-neck cancers can be improved to 14 months (cf. 226 days by using surface illumination PDT). PDT is thus a therapeutic option that may prove a useful addition to the armamentarium of the integrated head and neck oncology team.
Head-and-Neck Cancers -A Continuous Challenge to the Oncologists
Because of the complex regional anatomy, head-and-neck cancers constitute a unique category of human malignancy. Every year, there are about 363,100 new cases of head-and-neck cancers over the world (81,600 cases in Europe) (1, 2). The incidence varies considerably with different countries. For example, nasopharyngeal carcinoma (NPC) is common in Southeast China, Hong Kong, Singapore and Taiwan but is rare in the Western countries. Globally, the incidence of oral cavity cancer is highest in India and Southeast Asia, while Western Europe has the highest incidence of oral cavity cancer in the Western countries (1, 2). The mortality rate varies, on the other hand, with the site and stage of the primary tumors. Overall, thyroid cancers carry the best prognosis while oral cavity cancers have the worst prognosis (1, 3) . For oral cavity cancers, the probability of maintaining local control at two years for patients with T 1 or T 2 squamous cell carcinoma (SCC) is 75-85% (4). Although some early head-and-neck cancers are cured effectively, the overall outcome remains unsatisfactory. The overall survival rates have remained unchanged since 1974 at around 55% for white people and have declined slightly for blacks (down from 36% to 33%) (2, 3, 5, 6) .
Although chemotherapy plays an important role in the treatment of some headand-neck cancers such as NPC (7, 8) , the mainstay of treatments for most of the head-and-neck cancers are surgery and radiotherapy, either alone or in combination. Surgery is an effective measure for early stage cancers. However, because of the specialized function of the head-and-neck region, surgical resection, even of small volume tumors, can cause functional and aesthetic impairment leading to withdrawal and social isolation. For advanced tumors, major surgical ablation plus local or free-flap reconstruction leads to significant aesthetic and functional morbidity. Radiotherapy, although with less impact on the structural integrity, carries acute toxicities and long-term complications to the patients. Xerostomia, speech disorder, dysphagia, pain, osteoradionecrosis or depression develop long after completion of treatment, and greatly reduce the patients' quality of life (9-11). It might be possible to justify the sacrifice of life quality for patients if survival were improved. However, despite the advances in oncological disciplines during the last decades, about half of the headand-neck cancer patients still succumb to their disease.
The management of head-and-neck cancers is further complicated by the occurrence of multiple primary malignancies. It is now accepted that the incidence of multiple primary SCC occurring in the upper aero-digestive tract can be as high as 20-30% (12, 13). The pathogenesis is not well understood, but it is probably related to the effects of multiple carcinogens. Slaughter et al. had suggested the term "field cancerization" to describe the situation where the entire region of upper aero-digestive tract mucosa is exposed to carcinogen, thereby increasing the risk of that tissue developing multiple independent pre-malignant and malignant areas (14) . It is now known that sequential impairment of tumor suppressor genes and activation of oncogenes are also responsible for the pathogenesis of multiple primary head-and-neck cancers (15). It is also known that in the younger population or in patients with "condemned mucosa" the incidence of radiation-induced malignancies is greatly increased (16). Management of a second primary cancer within the previously operated or irradiated field is even more difficult. The difficulties associated with treating these tumors suggest a need for alternative treatments that are less destructive, repeatable, and compatible with previous and subsequent radiotherapy and surgery.
Basic Mechanisms of Photodynamic Therapy
Photodynamic therapy (PDT) has been known for about a century, but it wasn't until the mid-seventies that there was a real breakthrough. Dougherty and his colleagues reported a cure of 48% of rats and mice with subcutaneously implanted tumors treated with hematoporphyrin derivative (HpD) mediated PDT(17). Three years later, the same group published highly encouraging results of the first clinical trial on 25 patients with various types of tumors, mainly metastatic, effectively inactivated by PDT (18) . PDT is a site-specific, non-thermal, minimally invasive procedure. It requires a photoactive substance (photosensitizer) to absorb light (photon) of a specific wavelength matching the absorption characteristics of the photosensitizing agent. On illumination, the photosensitizer is activated from a stable electronic ground state, to a short-lived, highly unstable excited state, then to a metastable triplet state. The triplet state of the photosensitizer has a relative long lifetime and can undergo either electron transfer to a nearby suitable molecule (e.g. membrane lipid) (type I reaction) or energy transfer to the surrounding molecular oxygen (type II reaction) (19) . Hydrogen peroxide and other superoxide radical anions are produced directly from the type I photodynamic reaction, while the non-radical, highly reactive singlet oxygen species are produced through the type II photodynamic reaction. Both reactions may occur simultaneously and are responsible for the photoinactivation effects of PDT. However, it is generally accepted that the type II photodynamic reaction is probably the main mechanism of PDT-induced cell death. In addition to the 2 types of photodynamic reactions, vascular shutdown to the tumor as well as PDT-induced immunological responses are also involved in the tumoricidal effects of PDT (20).
Advantage of PDT over Conventional Measures for Headand-Neck Cancers
Most of the photosensitizers are selectively retained by the cancer cells due to unknown mechanisms. Accordingly, in clinical practice, the photosensitizer is administered first and then illumination is carried out when a differential in photosensitizer concentration between the tumor tissue and adjacent normal tissue has developed. This protocol encourages neoplastic tissue necroses with some preservation of the normal tissue. Because PDT is a non-thermal reaction, the necrosis is localized and healing takes place with little scarring, and good preservation of function (21, 22) . Surgery, radiotherapy, or chemotherapy does not preclude the use of PDT, nor will PDT compromise the subsequent use of any other treatment (23). Unlike ionizing irradiation, PDT is repeatable without cumulative tissue toxicity (24). Because of these characteristics, PDT is an ideal option in the treatment of head-and-neck cancers.
Photosensitizers for Clinical Head-and-Neck Cancer Treatment
To verify the safety and efficacy of PDT in the treatment of head-and-neck cancers, many clinical studies have been performed during the last 2 decades. Although new photosensitizers have been synthesized, only a few of them have been used in clinical head-and-neck cancer patients. Table I (24). Photofrin absorbs light maximally at about 400 nm; however, the absorption band that is used clinically in the red at about 630 nm is relatively weak. Therefore, the depth of effect for photofrin is limited to about 0.5 cm. Clinically, the major drawback of photofrin is the prolonged skin photosensitivity, sometimes longer than 4-6 weeks after sensitization (25). The second photosensitizer used in head-and-neck oncology is 5-aminolaevulinic acid (ALA). ALA is a naturally occurring photosensitizing precursor that is metabolized to a photoactive endogenous intermediate substance, protoporphyrin IX (PPIX), in the mitochondria matrix (26). ALA can be given topically, orally, or intravenously; and its active metabolite, PPIX, can be activated by red, green, and even blue light. There are great variations in the amount of PPIX accumulated following ALA administration in different organs and tissues. A notably higher level of ALA induced PPIX was found in the epithelial lining tissues-urothelium, endometrium, and mucosa of the hollow organs of the gastrointestinal tract (27-29) than in the underlying submucosa and muscle layers. The specific distribution of ALA makes it a good candidate for the treatment of superficial, mucosa lesions. But it is also because of this limited tissue penetration (< 0.2 cm) that makes ALA not suitable for treating deep, bulky tumors. Meta tetrahydroxyphenyl chlorin (mTHPC, temoporfin, Foscan) is the third photosensitizer that is used in clinical head-and-neck cancer patients. Foscan has a strong absorption peak in the red part of the spectrum at 652 nm, which gives better tissue penetration than at the 630 nm required for photofrin (30). Reflecting to the depth of treatment, Foscan-PDT-induced necrosis can reach to about 1 cm in depth. Foscan is also a much more effective generator of singlet oxygen species than HpD. So the light doses used in Foscan-PDT are far less than the first generation photosensitizers, and the treatment time can be shortened to only a few minutes. Another advantage of Foscan-PDT is skin photosensitivity to bright light lasts for only about 2-3 weeks, up to a maximum of about a month.
The Evolution of Head-and-Neck Cancer PDT
The clinical reports of implementing PDT in the treatment of head-and-neck cancers can be traced back to about 20 years ago, and the whole span can be divided into halves. Before 1994, all the studies were performed using the first generation photosensitizers, e.g. HpD or Photofrin. The studies established that PDT could be an important adjuvant treatment modality for head-and-neck cancers. It also laid the foundation of future development of clinical PDT. After 1994, PDT has got regulatory approval and several second-generation photosensitizers have been developed and used in pre-clinical and clinical trials. Unfortunately, because of the financial problem and collapse of the manufacturer of Foscan, the most potent photosensitizer for head-and-neck cancer treatment to date, the development of head-and-neck PDT was slowed down. Recently, Foscan has been back to the market again and many clinical trial results using Foscan-PDT to treat head-and-neck cancers will soon be published.
PDT with the First Generation Photosensitizers (Table II) In 1985 PDT with the Second Generation Photosensitizers (Table III) Grant et al. published the first report of using ALA-PDT in the treatment of oral cavity cancers (46). Three of the four tumors showed marked necrosis after PDT treatment.
Fan et al. continued the study and implemented ALA-PDT to treat 18 patients with premalignant and malignant lesions of the oral cavity (47). All 12 patients with dysplasia improved after PDT, while only 2/6 patients with carcinomas gained CR. They also studied the depth of necrosis produced by ALA-PDT. Although complete epithelial necrosis was present in all cases, the depth of necrosis by ALA-PDT was only 0.1 to 1.3 mm (47). Another study by Sieron et al. also showed that ALA-PDT was not efficient enough to treat head-and-neck SCCs (48). In general, ALA-PDT is good for head-and-neck premalignant lesions (over 80% CR rate) but not efficient enough to eradicate malignant tumors.
Foscan is so far the most potent licensed photosensitizer for PDT. The maximum depth of necrosis produced by Foscan-PDT can be up to 1 cm. Fan et al. used Foscan-PDT to treat 20 patients with premalignant or malignant tumors in the mouth. CR was achieved in 9/12 SCC patients (49). Kubler et al. treated 25 patients with early stage (Tis-T2) lip cancers and reported a 96% CR rate at 3 months (50). Only 2 of the complete responders recurred (one 4 months and the other one 18 months after PDT) during the follow-up. A large-scale multi-center study using Foscan-PDT for early stage (Tis, T1 and early T2) oral cancers has been completed recently (51). The CR rate at 2 years was 75% after one PDT treatment. For those who failed the primary PDT treat- 
Conclusion
Although it is very difficult to treat head-and-neck cancers satisfactorily, PDT seems to be particularly suited for these tumors because it has little effect on underlying functional structures and has an excellent cosmetic outcome. Studies in the past have confirmed that PDT is a safe and effective means in the treatment of head-and-neck cancers. Recent developments in biochemical and molecular technology have improved the specificity and efficacy of photosensitizers. Treatment time is greatly reduced, while depth of tumor necrosis is greatly increased. Improvement in the light delivery system and implementing interstitial treatment into PDT has extended the indication of PDT from surface, superficial tumors to deep-seated, bulky tumors. PDT is a therapeutic option that may prove a useful addition to the armamentarium of the integrated head and neck oncology team. 
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